Bristol-Myers Squibb

Sr. Manager, Operational Excellence in Devens, MA

Devens, Massachusetts, United States

$150,000 – $200,000Compensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, ManufacturingIndustries

Requirements

The Senior Manager, OpEx requires experience in developing and implementing operational strategies, with a focus on embedding Operational Excellence (OpEx) methodologies like Lean Six Sigma and Continuous Improvement. Familiarity with data analysis for decision-making and a strong understanding of continuous improvement principles are also expected.

Responsibilities

The Senior Manager, OpEx will provide Operational Excellence support to the Biologics Manufacturing department, increase process efficiency and reduce operating costs, improve data availability, drive continuous improvement within the Devens Biologics Manufacturing, embed OpEx foundational skills, drive Tier meetings and visual factory, collaborate with various teams to develop metrics, drive CI project portfolios, participate in site Kaizen events, act as the primary OpEx point of contact, and introduce and maintain continuous improvement program offerings.

Skills

Lean Six Sigma
Continuous Improvement
Data Analysis
Process Efficiency
Metrics
Kaizen
Visual Factory

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI